Insider buying last 90 days
No open-market insider purchases were filed for ICLR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week's news for ICON centers on the launch of its FIRECREST AI-Directed Video Engine, a tool designed to automate and standardize clinical trial communications for sites and patients, described as changing the economics of site communications. Alongside this product news, several insider transactions surfaced, including CEO Edward Barry Balfe's sale of 5,175 shares worth $1,069,441 and director Ciaran Murray's sale of 3,452 shares at $205.6650 per share, with Murray retaining 17,000 shares. A Morningstar analyst report from 29 October also pointed to strong healthcare demand and robust bookings supporting growth recovery for Icon in 2027.
ICON shares closed at $207.59, up 1.4%, sitting above both the 50-day average of $176.02 and the 200-day average of $146.43. The stock's one-month return stands at 26.4% and its six-month return at 74.5%, with the 52-week range spanning $66.57 to $219.04. The GekkoIndex reads 47.3, placing it in the Neutral zone, while the price sits 3.1% above Gekko Fair Value of $201.42.
Looking ahead, ICON's next earnings report is scheduled for 24 February 2027, 101 days away, placing it outside a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal was recorded, with call premium of $1,830,395 against no put premium. Seasonality data shows the next 20 trading days have averaged a 3.5% gain over 5 years, rising in 4 of them. Analyst consensus among 14 firms shows 8 buy and 6 hold ratings, with a consensus target of $231.29.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
ICON scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $194.65 is above the 50-day ($179.01) and 200-day ($146.69) averages, and the 50-day is above the 200-day.
See the chart54.4, Neutral
Reading 54.4 is in the Neutral zone.
See the GekkoIndex1.9% below
Price is within 5% of Gekko Fair Value (1.9% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings+1.9% on average
From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
ICON closed at $194.65 on Nov 13, 2026, +19.1% over the past year, inside a 52-week range of $66.57 to $219.04.
Use the left and right arrow keys to read daily values.
Put ICLR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
ICON provides outsourced services that support the development and commercialization of new medical products. It works across the full clinical development process, from selecting compounds through Phase I-IV studies, and is recognized for managing complex, multi-stage research programs on behalf of other organizations rather than running its own drug pipeline.
The company's offerings span clinical trial management, consulting, contract staffing, and commercial strategy work such as trial design and post-market positioning. It also runs laboratory operations covering bioanalytical, biomarker, vaccine, and central lab testing, alongside services like decentralized trials, medical imaging, and real-world data analysis. Its customers include pharmaceutical, biotechnology, and medical device companies, as well as government and public health bodies, and it has formed a strategic alliance with Advarra to build a connected network of clinical trial sites.
ICON was incorporated in 1989 and is based in Dublin, Ireland, with operations extending across Europe, the United States, and other regions. Its shares are listed on the NASDAQ under the ticker ICLR.
ICON’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.4, in the Neutral zone, up 6.8 points over five sessions.
Up 6.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | −3.7% | −3.6% | ||
| Accumulation | 251 | +0.6% | −0.8% | ||
| Neutral (current zone) | 340 | +0.2% | 0.0% | ||
| Distribution | 54 | +0.3% | +5.5% | ||
| Selling | 9 | Too few readings yet | |||
Average ICLR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
ICON trades 1.9% below Gekko Fair Value of $198.44, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what ICON shares are worth, recalculated every trading day.
$198.44
Gekko Fair Value, Nov 14, 2026
1.9% below fair value · About fair value
At the end of Aug 2026 the price was 11.6% below the estimate.
No open-market insider purchases were filed for ICON, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ICLR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ICLR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
ICON has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bearish flow on Oct 30, $1.83M in unusual premium.
0of the funds Gekko tracks hold ICLR.
ICON reports on Feb 24, 2027, before the open (101 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 24, 2027
Expected before the open, 101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 27, 2026 | $2.66 est $2.62 | $2.02B est $2.01B | +16.5% |
| Jul 29, 2026 | $2.56 est $2.55 | $2.06B est $2.00B | −8.2% |
| May 27, 2026 | $2.52 est $3.13 | $2.11B est $1.98B | +20.2% |
| Feb 25, 2026 | $0.00 est $3.31 | — | +2.0% |
| Oct 22, 2025 | $3.31 est $3.28 | $2.04B est $2.01B | −6.9% |
| Jul 23, 2025 | $3.26 est $3.18 | $2.02B est $1.98B | +20.7% |
| Apr 30, 2025 | $3.19 est $3.09 | $2.00B est $2.01B | −2.7% |
| Feb 19, 2025 | $3.43 est $3.43 | $2.04B est $2.04B | +7.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for ICON is $231.29, +18.8% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Mizuho Securities | $228 | +17.1% |
| Oct 29 | Robert W. Baird | $249 | +27.9% |
| Oct 29 | Citi | $215 | +10.5% |
| Oct 29 | UBS | $236 | +21.2% |
| Oct 29 | TD Cowen | $254 | +30.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, ICON averaged +1.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 2 of 5 |
| Next 10 trading days | +1.7% | 3 of 5 |
| Next 15 trading days | +1.3% | 3 of 5 |
| Next 20 trading days | +1.9% | 3 of 5 |
| Next 30 trading days | +4.4% | 4 of 5 |
For scale, ICLR’s typical 20-trading-day move in either direction is about 6.7%.
ICON’s market cap is $14.58B, with a P/E ratio of 80.2 and revenue of $8.23B over the last twelve months.
Coverage of ICON this week reads neutral: 1 positive, 5 neutral and 0 negative headlines.
ICON’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Accumulation | 0.6% above |
| CTASCintas | Neutral | 22.3% above |
| PYPLPayPal | Neutral | 5.3% above |
| XYZBlock | Neutral | 15.1% above |
| FISVFiserv | Distribution | 38.0% below |
| CPAYCorpay | Distribution | 5.1% below |
A peer links to its own page where one exists.
ICON’s market cap is $14.58B at the Nov 13, 2026 close of $194.65, with 74.92M shares outstanding. The shares trade on a P/E ratio of 80.2.
The consensus analyst 12-month price target for ICON is $231.29, +18.8% from the last close. Of the 14 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate ICON is about fair value: the Nov 13, 2026 close of $194.65 is 1.9% below Gekko Fair Value of $198.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
ICON is expected to report on Feb 24, 2027, before the market opens (101 days away). Analysts expect earnings of $2.83 per share on revenue of $2.04B. ICON beat the earnings estimate in 6 of its last 8 reports, moving 10.5% on average across the report.
ICON’s 52-week high is $219.04 and its 52-week low is $66.57; it closed at $194.65 on Nov 13, 2026, +19.1% over the past year. Over the last five years the shares peaked at $347.72 on Jul 16, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in ICON over the last 30 days, with $1.83M of flagged premium in calls and $0 in puts. The latest, bearish flow, was on Oct 30, 2026 with $1.83M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.